GLP-1(1~37) 诱导人类胚胎小肠 上皮细胞表达胰岛素

胶原酶消化法分离培养人类胚胎小肠的上皮细胞,应用胰高血糖素样肽 1 (glucagon-like peptide 1 (1~37),GLP-1) 诱导小肠上皮细胞向胰岛素分泌细胞分化,免疫组化方法对分化的和未分化的细胞进行鉴定, RT-PCR 检测胰岛内分泌细胞相关基因的表达 . 结果成功分离培养出人类小肠上皮细胞,免疫组化证明细胞表达小肠上皮的标志物细胞角蛋白 18 和 19 ,同时细胞也表达胰高血糖素和生长抑素,但无胰岛素表达 . GLP-1(1~37) 诱导小肠上皮细胞 6 天, RT-PCR 显示胰十二指肠同源异型基因盒 1 (pancreatic duodenal homeobox-1 , PDX-1) 、葡萄糖转运蛋白 2 (glucose transporter-2 , GLUT-2) 和胰岛素基因均有表达,免疫组化也检测到胰岛素阳性小肠上皮细胞 . 未用 GLP-1(1~37) 诱导小肠上皮细胞为对照的 RT-PCR 显示 PDX-1 、 GLUT-2 也表达,但无胰岛素 mRNA 和蛋白质的表达 . 研究表明 GLP-1(1~37) 能够诱导人类胚胎小肠上皮细胞向胰岛素分泌细胞分化 .     

治疗糖尿病的短肽药物GLP-1在毕赤酵母中的分泌表达

利用毕赤酵母表达治疗糖尿病的短肽药物GLP-1(胰高血糖素样肽-1)。以pUC18GLP-1 为模板进行PCR,将获得的GLP-1基因片段克隆到pMD18T-vector上,然后将SmaI和NotI双酶切获得的基因小片段插入到表达载体pPIC9上,完成表达载体pPIC9GLP-1的构建,SacI线性化重组质粒,通过醋酸锂转化法转化毕赤酵母GS115感受态细胞,成功构建了能够分泌抗二肽酶Ⅳ降解的长效促胰岛素激素的毕赤酵母工程菌株。结果表明毕赤酵母6号菌株的GLP-1分泌表达产量最高可达 100．00 mg／L．实现了GLP-1在毕赤酵母中的表达,为进一步开发治疗糖尿病新型短肽药物的研究奠定了基础。     

GLP-2对小鼠小肠黏膜的作用及不同脏器分布的影响

目的：观察胰高血糖素样肽-2对小鼠小肠黏膜的作用效果及其受体在不同脏器的分布和表达。方法：选用5-6周龄的雄性健康BALB/C小鼠,体重17～20g。随机分为3组。对照组8只;脑内注射GLP-2组9只,每天按25μg/kg脑内注射GLP-2液2次,连续3天;腹腔注射GLP-2组9只,每天按250μg/kg腹腔注射GLP-2液2次,连续3天。3天后,处死小鼠,做组织切片进行HE染色,观察小鼠小肠黏膜的组织学变化,用免疫组化方法检测GLP-2R在不同脏器的表达和分布。结果：小鼠经腹腔注射GLP-2后,小肠不同肠段黏膜的绒毛高度较对照组明显增加（P〈0.05）,脑内注射组的肠黏膜无明显形态学变化;GLP-2R在小鼠胃、空肠与结肠部位均有表达,而食管与肝显阴性;腹腔注射组的GLP-2R表达较对照组显著下调（P〈0.05）。结论：GLP-2能刺激小肠黏膜上皮增厚,增加小肠不同肠段黏膜的绒毛高度;小鼠的胃、空肠与结肠经GLP-2（腹腔注射）处理后其受体表达下调。     

改变大鼠促性腺激素细胞内cAMP含量对卵泡刺激素分泌的影响

目的:分析大鼠卵泡刺激素(FSH)分泌的受体后信号转导机制。方法:将促性腺激素(GTH)细胞用毛喉素(FSK)或腺苷酸环化酶抑制剂SQ22536处理后,用促性腺激素释放激素脉冲刺激,再用酶联免疫吸附法检测其FSH分泌量,并与空白对照组比较。结果:FSK能显著提高GTH细胞中环磷酸腺苷(cAMP)含量,SQ22536能显著降低GTH细胞中的cAMP含量,FSK和SQ22536都不会影响GTH细胞的蛋白激酶C活性,GTH细胞cAMP含量的变化对FSH分泌的影响不显著。结论:cAMP-PKA(蛋白激酶A)不是FSHβ亚基分泌的受体后信号转导途径。     

一种GLP-1过表达肠类器官构建的方法

胰高血糖素样肽1(glucagon-like peptide 1,GLP-1)作为一种肠促胰岛素,主要由肠道L细胞分泌,由于其能够有效促进胰岛素的释放从而降低血糖,因此GLP-1及其类似物在2型糖尿病的治疗上具有良好的应用前景.本研究优化了慢病毒感染类器官的方法,利用该方法成功构建了GLP-1过表达的小鼠小肠类器官(o...     

室旁核注射GLP-1 及拮抗剂对大鼠胃组织nesfatin-1 表达的影响

目的:探讨下丘脑室旁核(pareventricular,PVN)注射胰高血糖素样肽-1(GLP-1)及其受体拮抗剂Exendin(9-39)后胃组织核组蛋白2(NUCB2)/nesfatin-1表达的影响。方法:选取48只雄性Wistar大鼠,随机分为6组,生理盐水组,四种不同剂量GLP-1组(0.003 nmol/10μL,0.03 nmol/10μL,0.3 nmol/10μL,3 nmol/10μL),30 nmol Exendin(9-39)+3 nmol GLP-1(E+G)组,每组8只。PVN区埋置套管并按每组要求分别经套管给予GLP-1及Exendin(9-39)等药物。给药2小时后处死大鼠并取胃组织,实时荧光定量RT-PCR法检测各组胃组织NUCB2 m RNA表达。另外生理盐水组,3 nmo L GLP-1组及E+G组每组分别随机取6只大鼠的部分胃组织,用免疫组织化学法测胃粘膜NUCB2/nesfatin-1蛋白的表达情况。结果:实时荧光定量RT-PCR法发现3 nmo L GLP-1组大鼠胃组织NUCB2 m RNA表达量高于生理盐水组,差异有统计学意义(P0.05),而其余各组大鼠胃组织NUCB2 m RNA表达与生理盐水组比较无统计学差异(P0.05)。免疫组化结果显示3 nmo L GLP-1组胃粘膜NUCB2/nesfatin-1蛋白表达与生理盐水组、E+G组比较有统计学差异(P0.05),生理盐水组大鼠胃粘膜NUCB2/nesfatin-1蛋白表达与E+G组比较无明显差异(P0.05)。结论:PVN注射GLP-1能够促进胃组织NUCB2/nesfatin-1的表达,这一作用可能是通过激活GLP-1受体来完成的。     

GLP-1-IgG4-Fc融合蛋白的表达与鉴定

将合成的人胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)突变体基因与IgG4抗体的Fc部分进行融合获得GLP-1-IgG4-Fc片段,获得的基因片段与pXC17.4载体进行连接,用电转化方法将线性化质粒稳定转染CHO-K1细胞,通过Clone Pix 2筛选出高表达细胞株,产量达1.5g/L。收集培养上清并经Protein A和Source 30Q纯化,得到的GLP-1-IgG4-Fc融合蛋白,SDS-PAGE纯度高于95%,高效液相色谱(high performance liquid chromatography,HPLC)纯度和毛细管区域凝胶电泳(capillary zone electrophoresis,CZE)纯度均不低于80%,尺寸排阻层析(size-exclusion chromatography,SEC)纯度高于99%。经质谱和肽图谱测定,分子量与理论值一致,肽图谱序列与对照品高度一致。生物学活性分析表明,GLP-1-IgG4-Fc融合蛋白具有促进表达有GLP-1受体的HEK293细胞分泌环磷酸腺苷(cyclic adenosine monophosphate,c AMP)的活性,并且该活性与对照品高度相似。     

中枢注射Nesfatin-1与Exendin(9-39)对大鼠摄食和胃肠动力调节的影响

目的:探讨下丘脑室旁核注射GLP-1R拮抗剂Exendin(9-39)对Nesfatin-1所致大鼠摄食和胃肠动力改变的影响及作用机制。方法:选择40只雄性Wistar大鼠,随机分成正常对照组(NC组)、Nesfatin-1组(NS组)、Exendin(9-39)组(ES组)、Nesfatin-1联合Exendin(9-39)组(NE组)。采用下丘脑室旁核(PVN)埋置套管并分别给予以上药物干预,干预前和干预后的12小时、24小时记录和比较各组大鼠的摄食、饮水及体重变化。2天后,采用甲基纤维素-酚红溶液灌胃法测各组大鼠胃排空率,实时荧光定量法(RT-PCR)检测下丘脑及胃组织GLP-1Rm RNA的表达。结果:与基础摄食量比较,NS组大鼠给药后12 h、24 h的摄食量减少(P0.05),NE组大鼠给药后12 h、24 h的摄食量减少(P0.05),但较NS组增加(P0.05);与基础饮水量比较,NS组、NE组给药后12 h饮水量减少(P0.05);与基础体重比较,NS组大鼠给药后12 h、24 h的体重降低(P0.05),NE组大鼠给药后12 h的体重降低(P0.05),但较NS组增加(P0.05);NS组大鼠给药后胃排空率较NC、NE组大鼠显著下降(P0.05),NS组大鼠下丘脑GLP-1Rm RNA的表达量较NC组增加(P0.05)。结论:中枢给予GLP-1R拮抗剂能减弱Nesfatin-1引起的摄食抑制、胃排空延迟及体重下降效应,Nesfatin-1可能通过与GLP-1的协同作用参与摄食及胃肠动力的调节。     

取代环丁烷结构的非肽类胰高血糖素样肽-1受体激动剂

应用胰高血糖素样肽-1（glucagon-like peptide-1,GLP-1）及其类似物治疗2型糖尿病是代谢性疾病研究领域近年来的热点,尤其是胰高血糖素样肽-1独特的作用机制倍受业界的关注。它能同时作用于2型糖尿病的多个发病环节,在有效降低血糖的同时,避免低血糖的发生并能减轻体重。但这类药物因其多肽性质而存在诸多的使用限制（如需反复注射）。简要介绍一类取代环丁烷结构的新型非肽类胰高血糖素样肽-1受体小分子激动剂的发现过程、基本药理学特征和体内抗糖尿病和抗肥胖症效应。     

稳定表达GLP-1类似物的CHO细胞株的构建及培养工艺研究

胰高血糖素样肽-1(Glucagon like peptide-1,GLP-1)是一种治疗II型糖尿病的潜在药物,针对其在体内半衰期短和在酵母中表达的批次间不稳定等问题,课题组前期对其进行改造,成功利用p MH3载体在中国仓鼠卵巢(Chinese hamster ovary,CHO)细胞中表达人血清白蛋白(human serum albumin,HSA)融合蛋白NGGH[6×His-tag+Ek+2×GLP-1(A2G)+HSA]。现利用新型载体pcDNA3.1,构建含融合蛋白的真核表达质粒pcDNA3.1/NGGH,经电击转染转入CHO细胞中。G418抗性压力筛选后利用一种新型的细胞成像系统高效快速地筛选出高表达单克隆株。表达的目的蛋白经WB(Western blot)验证显示,产物具有GLP-1和HSA的双抗原性。经悬浮驯化稳定后,通过批次筛选得到一株稳定的高表达细胞株,产量为58mg/L。利用5L AP20激流式生物反应器扩大培养重组细胞,对p H和溶氧控制条件进行了优化。结果显示,在p H6.8~7.4,溶氧(dissolved oxygen,DO)两相控制的条件下,蛋白质最终表达量可达148mg/L。     

GLP-1(7-36)amide-stimulated insulin secretion in rat islets is sodium-dependent

We examined the Na(+)-dependency of the effects of GLP-1(7-36)amide in normal, overnight cultured rat islets. It was found that GLP-1(7-36)amide stimulated insulin secretion, 45Ca(2+)-efflux, and 86Rb(+)-efflux from prelabelled islets. All these effects were abolished by omitting Na+ from the medium and replacing it with N-methyl-glucamine. This suggests that GLP-1(7-36)amide stimulates insulin secretion by depolarizing the beta-cells by increasing their permeability to Na+.     

GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide

Objective: Glucagon‐like peptide‐1 (GLP‐1) (7–36) amide is a glucoregulatory hormone with insulinotropic and insulinomimetic actions. We determined whether the insulinomimetic effects of GLP‐1 are mediated through its principal metabolite, GLP‐1 (9–36) amide (GLP‐1m). Methods and Procedures: Glucose turnover during two, 2‐h, euglycemic clamps was measured in 12 lean and 12 obese (BMI <25 or >30 kg/m²) male and female subject volunteers with normal oral glucose tolerance test. Saline or GLP‐1m were infused from 0 to 60 min in each study. Additionally, seven lean and six obese subjects underwent a third clamp in which the GLP‐1 receptor (GLP‐1R) antagonist, exendin (9–39) amide was infused from ?60 to 60 min with GLP‐1m from 0 to 60 min. Results: No glucose infusion was required in lean subjects to sustain euglycemia (glucose clamp) during saline or GLP‐1m infusions. However, in obese subjects glucose infusion was necessary during GLP‐1m infusion alone in order to compensate for a marked (>50%) inhibition of hepatic glucose production (HGP). Plasma insulin levels remained constant in lean subjects but rose significantly in obese subjects after termination of the peptide infusions. During GLP‐1R blockade, infusion of glucose was immediately required upon starting GLP‐1m infusions in all subjects due to a more dramatic reduction in HGP, as well as a delayed and modest insulinotropic response. Discussion: We conclude that GLP‐1m potently inhibits HGP and is a weak insulinotropic agent. These properties are particularly apparent and pronounced in obese but only become apparent in lean subjects during GLP‐1 (7–36) receptor blockade. These previously unrecognized antidiabetogenic actions of GLP‐1m may have therapeutic usefulness.     

Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development.

The expression of glucagon-like peptide-1 (GLP-1) receptor and the effects of GLP-1-(7-36) amide (t-GLP-1) on glucose metabolism and insulin release by pancreatic islets during rat development were studied. GLP-1 receptor mRNA was found in significant amounts in pancreatic islets from all age groups studied, GLP-1 receptor expression being maximal when pancreatic islets were incubated at physiological glucose concentration (5.5 mM), but decreasing significantly when incubated with either 1.67 or 16.7 mM glucose. Glucose utilization and oxidation by pancreatic islets from fetal and adult rats rose as a function of glucose concentration, always being higher in fetal than in adult islets. The addition of t-GLP-1 to the incubation medium did not modify glucose metabolism but gastric inhibitory polypeptide and glucagon significantly increased glucose utilization by fetal and adult pancreatic islets at 16.7 mM glucose. At this concentration, glucose produced a significant increase in insulin release by the pancreatic islets from 10-day-old and 20-day-old suckling rats and adult rats, whereas those from fetuses showed only a significant increase when glucose was raised from 1.67 to 5.5 mM. t-GLP-1 elicited an increase in insulin release by pancreatic islets from all the experimental groups when the higher glucose concentrations were used. Our findings indicate that GLP-1 receptors and the effect of t-GLP-1 on insulin release are already present in the fetus, and they therefore exclude the possibility that alterations in the action of t-GLP-1 are responsible for the unresponsiveness of pancreatic beta cells to glucose in the fetus, but stimulation of t-GLP-1 release by food ingestion in newborns may partially confer glucose competence on beta cells.     

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

Glucagon-like peptide 1 (GLP-1) lowers glycemia by modulating gastric emptying and endocrine pancreatic secretion. Rapidly after its secretion, GLP-1-(7-36) amide is degraded to the metabolite GLP-1-(9-36) amide. The effects of GLP-1-(9-36) amide in humans are less well characterized. Fourteen healthy volunteers were studied with intravenous infusion of GLP-1-(7-36) amide, GLP-1-(9-36) amide, or placebo over 390 min. After 30 min, a solid test meal was served, and gastric emptying was assessed. Blood was drawn for GLP-1 (total and intact), glucose, insulin, C-peptide, and glucagon measurements. Administration of GLP-1-(7-36) amide and GLP-1-(9-36) amide significantly raised total GLP-1 plasma levels. Plasma concentrations of intact GLP-1 increased to 21 +/- 5 pmol/l during the infusion of GLP-1-(7-36) amide but remained unchanged during GLP-1-(9-36) amide infusion [5 +/- 3 pmol/l; P < 0.001 vs. GLP-1-(7-36) amide administration]. GLP-1-(7-36) amide reduced fasting and postprandial glucose concentrations (P < 0.001) and delayed gastric emptying (P < 0.001). The GLP-1 metabolite had no influence on insulin or C-peptide concentrations. Glucagon levels were lowered by GLP-1-(7-36) amide but not by GLP-1-(9-36) amide. However, the postprandial rise in glycemia was reduced significantly (by approximately 6 mg/dl) by GLP-1-(9-36) amide (P < 0.05). In contrast, gastric emptying was completely unaffected by the GLP-1 metabolite. The GLP-1 metabolite lowers postprandial glycemia independently of changes in insulin and glucagon secretion or in the rate of gastric emptying. Most likely, this is because of direct effects on glucose disposal. However, the glucose-lowering potential of GLP-1-(9-36) amide appears to be small compared with that of intact GLP-1-(7-36) amide.     

GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

Glucagon-like peptide 1 (GLP-1) is a potent anti-hyperglycemic hormone currently under investigation for its therapeutic potential. However, due to rapid degradation by dipeptidyl peptidase IV (DPP IV), which limits its metabolic stability and eliminates its insulinotropic activity, it has been impossible to assess its true efficacy in vivo. In chloralose-anesthetized pigs given valine-pyrrolidide (to block endogenous DPP IV activity), the independent effects of GLP-1-(7-36) amide on glucose and insulin responses to intravenous glucose were assessed, and the metabolite generated by DPP IV, GLP-1-(9-36) amide, was investigated for any ability to influence these responses. GLP-1-(7-36) amide enhanced insulin secretion (P < 0.03 vs. vehicle), but GLP-1-(9-36) amide was without effect, either alone or when coinfused with GLP-1-(7-36) amide. In contrast, GLP-1-(9-36) amide did affect glucose responses (P < 0.03). Glucose excursions were greater after saline (121 +/- 17 mmol x l(-1) x min) than after GLP-1-(9-36) amide (73 +/- 19 mmol x l(-1) x min; P < 0.05), GLP-1-(7-36) amide (62 +/- 13 mmol x l(-1) x min; P < 0.02) or GLP-1-(7-36) amide + GLP-1-(9-36) amide (50 +/-13 mmol x l(-1) x min; P < 0.005). Glucose elimination rates were faster after GLP-1-(7-36) amide + (9-36) amide (10.3 +/- 1.2%/min) than after GLP-1-(7-36) amide (7.0 +/- 0.9%/min; P < 0.04), GLP-1-(9-36) amide (6.8 +/- 1.0%/min; P < 0.03), or saline (5.4 +/- 1.2%/min; P < 0.005). Glucagon concentrations were unaffected. These results demonstrate that GLP-1-(9-36) amide neither stimulates insulin secretion nor antagonizes the insulinotropic effect of GLP-1-(7-36) amide in vivo. Moreover, the metabolite itself possesses anti-hyperglycemic effects, supporting the hypothesis that selective DPP IV action is important in glucose homeostasis.     

Urinary excretion of glucagon-like peptide 1 (GLP-1) 7-36 amide in human type 2 (non-insulin-dependent) diabetes mellitus.

The urinary excretion of insulinotropic glucagon-like peptide 1 (GLP-1) was investigated as an indicator of renal tubular integrity in 10 healthy subjects and in 3 groups of type 2 diabetic patients with different degrees of urinary albumin excretion rate. No significant difference emerged between the groups with respect to age of the patients, known duration of diabetes, metabolic control, BMI, or residual beta-cell pancreatic function. Endogenous creatinine clearance was significantly reduced under conditions of overt diabetic nephropathy, compared with normo and microalbuminuric patients (p < 0.01). Urinary excretion of GLP-1 was significantly higher in normoalbuminuric patients compared to controls (490.4 +/- 211.5 vs. 275.5 +/- 132.1 pg/min; p < 0.05), with further increase under incipient diabetic nephropathy conditions (648.6 +/- 305 pg/min; p < 0.01). No significant difference resulted, in contrast, between macroproteinuric patients and non-diabetic subjects. Taking all patients examined into account, a significant positive relationship emerged between urinary GLP-1 and creatinine clearance (p = 0.004). In conclusion, an early tubular impairment in type 2 diabetes would occur before the onset of glomerular permeability alterations. The tubular dysfunction seems to evolve with the development of persistent microalbuminuria. Finally, the advanced tubular involvement, in terms of urinary GLP1 excretion, under overt diabetic nephropathy conditions would be masked by severe concomitant glomerular damage with the coexistence of both alterations resulting in a peptide excretion similar to control subjects.     

Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus

Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 are gastrointestinal hormones as well as neuropeptides involved in glucose homeostasis and feeding regulation, both peripherally and at the central nervous system (CNS), acting through the same GLP-1 receptor. Aminergic neurotransmitters play a role in the modulation of feeding in the hypothalamus and we have previously found that peripheral hormones and neuropeptides, which are known to modulate feeding in the central nervous system, are able to modify catecholamine and serotonin release in the hypothalamus. In the present paper we have evaluated the effects of GLP-1 and exendin-4 on dopamine, norepinephrine, and serotonin release from rat hypothalamic synaptosomes, in vitro. We found that glucagon-like peptide 1 (7-36) amide and exendin-4 did not modify either basal or depolarization-induced dopamine and norepinephrine release; on the other hand glucagon-like peptide 1 (7-36) amide and exendin-4 stimulated serotonin release, in a dose dependent manner. We can conclude that the central anorectic effects of GLP-1 agonists could be partially mediated by increased serotonin release in the hypothalamus, leaving the catecholamine release unaffected.     

Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog

A series of analogs of GLP-1(7-36) amide containing a Nepsilon-(2-[2-[2-(3-maleimidopropylamido)ethoxy]ethoxy]acetyl)lysine has been synthesized and the resulting derivatives were bioconjugated to Cys34 of human serum albumin (HSA). The GLP-1-HSA bioconjugates were analyzed in vitro to assess the stabilizing effect of bioconjugation in the presence of DPP-IV as well as GLP-1 receptor binding and activation. Compound 9 (CJC-1131) having the point of attachment to albumin at the C-terminal of GLP-1 and a D-alanine substitution at position 8 was identified as having the best combination of stability and bioactivity.     

室旁核注射胰高血糖素样肽-1对不同病程糖尿病大鼠胃排空的影响

目的:研究下丘脑室旁核(paraventricular nucleus,PVN)注射胰高血糖素样肽-1(GLP-1)对糖尿病早期大鼠胃排空的影响,并探讨其相关作用机制.方法:60只清洁级雄性Wistar大鼠随机分为正常对照组(NC组),糖尿病组(DM组),GLP-1干预组(GLP-1组),每组各20只,后两组腹腔注射链脲佐菌素(STZ)制备糖尿病模型,分别于注射STZ2周、6周后每组随机取半数进行实验,实验前于无菌条件下大鼠一侧下丘脑PVN区埋置套管,GLP-1组经套管注入GLP-1,NC组及DM组注入等体积生理盐水.酚红灌胃法检测胃排空率,酶联免疫吸附法(ELISA)测定血浆GLP-1浓度,半定量RT-PCR法测定胃窦、胃底GLP-1RmRNA表达.结果:注射STZ2周后,DM组较NC组胃排空率显著升高(P＜0.01).GLP-1组胃排空率低于DM组(P＜0.01),血浆GLP-1浓度高于DM组及NC组(P均＜0.05),胃窦GLP-1RmRNA表达明显高于DM组、NC组(P均＜0.01).注射STZ 6周后,DM组胃排空率高于NC组(P＜0.01).GLP-1组较DM组胃排空率显著降低(P＜0.01),血浆GLP-1浓度、胃窦GLP-1RmRNA表达显著高于DM组、NC组(P均＜0.01).结论:下丘脑PVN区注射GLP-1后,可减慢糖尿病大鼠初期加速的胃排空,原因可能与血浆GLP-1浓度及胃窦GLP-1RmRNA表达增加有关.